During the last session, ARS Pharmaceuticals Inc (NASDAQ:SPRY)’s traded shares were 1.29 million, with the beta value of the company hitting 1.01. At the end of the trading day, the stock’s price was $10.87, reflecting an intraday gain of 3.43% or $0.36. The 52-week high for the SPRY share is $18.51, that puts it down -70.29 from that peak though still a striking 30.54% gain since the share price plummeted to a 52-week low of $7.55. The company’s market capitalization is $1.06B, and the average trade volume was 1.32 million shares over the past three months.
ARS Pharmaceuticals Inc (SPRY) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. SPRY has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.11.
ARS Pharmaceuticals Inc (NASDAQ:SPRY) trade information
ARS Pharmaceuticals Inc (SPRY) registered a 3.43% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 3.43% in intraday trading to $10.87, hitting a weekly high. The stock’s 5-day price performance is 6.26%, and it has moved by -11.70% in 30 days. Based on these gigs, the overall price performance for the year is 24.80%.
The consensus price target of analysts on Wall Street is $22, which implies an increase of 50.59% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $18 and $30 respectively. As a result, SPRY is trading at a discount of -175.99% off the target high and -65.59% off the low.
ARS Pharmaceuticals Inc (SPRY) estimates and forecasts
In the rating firms’ projections, revenue will increase 60,007.33% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 15.46M as predicted by 5 analyst(s). Meanwhile, a consensus of 5 analyst(s) estimates revenue growth to 13.4M by the end of current fiscal year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -1.44%. While earnings are projected to return 0.70% in 2025.
SPRY Dividends
ARS Pharmaceuticals Inc is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 10.86 million shares, is of RA CAPITAL MANAGEMENT, L.P.’s that is approximately 11.2168% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $92.43 million.
Also, the Mutual Funds coming in first place with the largest holdings of ARS Pharmaceuticals Inc (SPRY) shares are Vanguard Total Stock Market Index Fund and SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF . Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 1.86 shares. This amounts to just over 1.92 percent of the company’s overall shares, with a $20.25 million market value. The same data shows that the other fund manager holds slightly less at 1.6, or about 1.65% of the stock, which is worth about $17.38 million.
